Clinical Trial Update: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of RC48-ADC in HER2-overexpressing gastric cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Overexpressing Gastric Carcinoma

Drugs mentioned

• RC48-ADC (Disitamab Vedotin)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | Phase 2 | Status: COMPLETED